Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Pure apathy and cognition in early stage drug-naïve patients with Parkinson’s disease
Movement Disorders
Movement Disorders Posters (7:00 AM-5:00 PM)
056
To compare the cognitive performance between non-demented, non-depressive drug-naïve Parkinson’s disease (PD) patients with and without apathy.
Apathy is associated with cognitive impairment in various stages of PD. However, the association between pure apathy and cognition in drug-naïve PD patients with early stage of motor symptoms has never been explored.
From the Parkinson’s Progression Markers Initiative database, 361 drug-naïve PD patients without depression and dementia were classified into the PD with pure apathy (n=47) and PD without apathy (n=314) group. Apathy was defined by score ≥1 on the MDS-UPDRS Part I Apathy. Patients with depression and dementia were excluded by Geriatric Depression Scale ≥ 5 and Modified Schwab & England ADL Functional Rating < 80% as cutoffs, respectively. The Montreal Cognitive Assessment was used for assessing global cognition. Five cognitive domains were evaluated by the Letter-Number Sequencing Test for working memory, the Symbol Digit Modality Test for processing speed, the Semantic Fluency Test for language function, the Benton Judgement of Line Orientation Test for visuospatial function, and the Hopkins Verbal Learning Test-revised for memory function.
The mean duration and severity of motor symptoms on the UPDRS-motor scale of overall patients were 6.82 (SD 6.73) months and 20.58 (SD 8.92) points, respectively. After controlling demographic characteristics, duration, and severity of motor symptoms, there was no difference in performance between two groups in global cognition and all cognitive domains.
Even previous studies proposed the association between apathy and cognitive impairments in various motor stages of PD, our study demonstrated that there was no difference in cognitive performance between drug-naïve PD patients with and without pure apathy in the early stage of motor symptoms. Future study should explore why apathy is only associated with cognitive impairment in the later stage, but not in the early stage of disease.
Authors/Disclosures
Amputch Karukote, MD
PRESENTER 		Dr. Karukote has nothing to disclose.
Smathorn Thakolwiboon, MD (Mayo Clinic Health System) Dr. Thakolwiboon has nothing to disclose.
Jie Pan, MD (torrance memorial) Dr. Pan has nothing to disclose.
Parunyou Julayanont, MD (Department of Neurology, Barrow Neurological Institute) Dr. Julayanont has nothing to disclose.